Lipoxins, resolvins, and protectins in the prevention and treatment of diabetic macular edema and retinopathy

Nutrition

Volumn 29, Issue 1, 2013, Pages 1-7

  Das, Undurti N ^a,b,c  

^a JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^b GAYATRI VIDYA PARISHAD COLLEGE OF ENGINEERING   (India)

^c UND LIFE SCIENCES   (United States)

Author keywords

Diabetic retinopathy; Inflammation; Lipoxins; Macular edema; Polyunsaturated fatty acids; Resolvins; Vascular endothelial growth factor

Indexed keywords

AGENTS ACTING ON THE EYE; BEVACIZUMAB; CD59 ANTIGEN; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INFLIXIMAB; INTERLEUKIN 6; LIPOXIN; LIPOXIN A; NITRIC OXIDE; PEGAPTANIB; PLACEBO; POLYUNSATURATED FATTY ACID; RANIBIZUMAB; RESOLVIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BLOOD VESSEL PERMEABILITY; CATARACT; CONJUNCTIVAL HEMORRHAGE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE PAIN; FATTY ACID METABOLISM; HUMAN; INTRAOCULAR PRESSURE; LOW LEVEL LASER THERAPY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIDE EFFECT; UVEITIS; VITRITIS;

ANTIBODIES, MONOCLONAL; CYTOKINES; DIABETIC RETINOPATHY; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LIPOXINS; MACULAR EDEMA; NEOVASCULARIZATION, PATHOLOGIC; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84870830821     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2012.02.003     Document Type: Review

References (85)

1. Shimizu E., Funatsu H., Yamashita H., Yamashita T., Hori S. Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema. Jpn J Ophthalmol 2002, 46:78-83.
2. Funatsu H., Yamashita H., Noma H., Mimura T., Yamashita T., Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002, 133:70-77.
3. Itoi K., Nakamura K., Oku H., Ishizaki E., Sugiyama T., Ueki M., et al. Relationship between diabetic macular edema and peripheral Th1/Th2 balance. Ophthalmologica 2008, 222:249-253.
4. Sfikakis P.P., Markomichelakis N., Theodossiadis G.P., Grigoropoulos V., Katsilambros N., Theodossiadis P.G. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care 2005, 28:445-447.
5. Sfikakis P.P., Grigoropoulos V., Emfietzoglou I., Theodossiadis G., Tentolouris N., Delicha E., et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care 2010, 33:1523-1528.
6. Giganti M., Beer P.M., Lemanski N., Hartman C., Schartman J., Falk N. Adverse events after intravitreal infliximab (Remicade). Retina 2010, 30:71-80.
7. Jingjing L., Xue Y., Agarwal N., Roque R.S. Human Muller cells expressVEGF183, a novel spliced variant of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1999, 40:752-759.
8. Wang J., Xu X., Elliott M.H., Meili Zhu M., Le Y.Z. Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes 2010, 59:2297-2305.
9. Vinores S.A., Youssri A.I., Luna J.D., Chen Y.S., Bhargave S., Vinores M.A., et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol 1997, 12:99-109.
10. Funatsu H., Yamashita H., Noma H., Mimura T., Yamashita T., Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002, 133:70-77.
11. Saishin Y., Saishin Y., Takahashi K., Lima e Silva R., Hylton D., Rudge J.S., Wiegand S.J., Campochiaro P.A. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003, 195:241-248.
12. Haritoglou C., Kook D., Neubauer A., Wolf A., Priglinger S., Strauss R., et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006, 26:999-1005.
13. Ng E.W., Adamis A.P. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci 2006, 1082:151-171.
14. Cunningham E.T., Adamis A.P., Altaweel M., Aiello L.P., Bressler N.M., D'Amico D.J., et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005, 112:1747-1757. Macugen Diabetic Retinopathy Study Group.
15. Do D.V., Schmidt-Erfurth U., Gonzalez V.H., Gordon C.M., Tolentino M., Berliner A.J., et al. The DA VINCI Study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology 2011, 118:1819-1826.
16. Mitchell P., Bandello F., Schmidt-Erfurth U., Lang G.E., Massin P., Schlingemann R.O., et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011, 118:615-625. RESTORE Study Group.
17. Subramanian M.L., Abedi G., Ness S., Ahmed E., Fenberg M., Daly M.K., et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye 2010, 24:1708-1715.
18. Martin D.F., Maguire M.G., Ying G.S., Grunwald J.E., Fine S.L., Jaffe G.J. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011, 364:1897-1908. Catt Research Group.
19. Okamoto N., Tobe T., Hackett S.F., Ozaki H., Vinores M.A., LaRochelle W., et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 1997, 151:281-291.
20. Miller J.W. Vascular endothelial growth factor and ocular neovascularization. Am J Pathol 1997, 151:13-23.
21. Chan-Ling T., Gock B., Stone J. The effect of oxygen on vasoformative cell division. Evidence that 'physiological hypoxia' is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci 1995, 36:1201-1214.
22. Yancoupoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
23. Ferrari G., Cook B.D., Terushkin V., Pintucci G., Mignatti P. Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol 2009, 219:449-458.
24. Brooks S.E., Gu X., Samuel S., Marcus D.M., Bartoli M., Huang P.L., Caldwell R.B. Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice. Invest Ophthalmol Vis Sci 2001, 42:222-228.
25. Keshet E. More weapons in the arsenal against ischemic retinopathy. J Clin Invest 2001, 107:945-946.
26. Ziche M., Morbidelli L., Choudhuri R., Zhang H.T., Donnini S., Granger H.T., Bicknell R. Nitric oxide synthase lies downstream from VEGF-induced but not basic fibroblast factor-induced angiogenesis. J Clin Invest 1997, 99:2625-2634.
27. Papapetropoulos A., Garcia-Cardena G., Madri J.A., Sessa W.C. Nitric oxide production contributes to angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997, 100:3131-3139.
28. Hood J.D., Meininger C.J., Ziche M., Granger H.J. VEGF upregulates ecNOS message, protein, and NO production inhuman endothelial cells. Am J Physiol Heart Circ Physiol 1998, 274:H1054-H1058.
29. Ghiso N., Rohan R.M., Amano S., Gerland R., Adamis A.P. Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. Invest Ophthalmol Vis Sci 1999, 40:1033-1039.
30. Tsurumi Y., Murohara T., Krasinski K., Chen D., Witzenbichler B., Kearney M., et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med 1997, 3:879-886.
31. Sennlaub F., Courtois Y., Goureau O. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest 2001, 107:717-725.
32. Kermorvant-Duchemin E., Sennlaub F., Sirinvan M., Brault S., Andelfinger G., Kooli A., et al. Trans-arachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneration. Nat Med 2005, 11:1339-1345.
33. Roy U., Loreau O., Balazy M. Cytochrome P450/NADPH-dependent formation of trans epoxides from trans-arachidonic acids. Bioorg Med Chem Lett 2004, 14:1019-1022.
34. Balazy M., Lopez-Fernandez J. Isomerization and nitro-oxidation of arachidonic acid by NO2. Adv Exp Biol Med 2003, 525:173-176.
35. Balazy M. Trans-arachidonic acids: new mediators of inflammation. J Physiol Pharmacol 2000, 51(4 Pt 1):597-607.
36. Kooli A., Kermorvant-Duchemin E., Sennlaub F., Bossolasco M., Hou X., Honore J.C., et al. Trans-arachidonic acids induce a heme oxygenase-dependent vasorelaxation of cerebral microvasculature. Free Radic Biol Med 2008, 44:815-825.
37. Jain K., Roy U., Ardelt B., Krishna U.M., Falck J.R., Pozarowski P., et al. 5E, 8Z, 11Z, 14Z-eicosatetraenoic acid, a novel trans isomer of arachidonic acid, causes G1 phase arrest and induces apoptosis of HL-60 cells. Int J Oncol 2005, 27:1177-1185.
38. Balazy M., Iesaki T., Park J.L., Jiang H., Kaminski P.M., Wolin M.S. Vicinal nitrohydroxyeicosatrienoic acids: vasodilator lipids formed by reaction of nitrogen dioxide with arachidonic acid. J Pharmacol Exp Ther 2001, 299:611-619.
39. Zghibeh C.M., Raj Gopal V., Poff C.D., Falck J.R., Balazy M. Determination of trans-arachidonic acid isomers in human blood plasma. Anal Biochem 2004, 332:137-144.
40. Smith L.E.H., Connor K.P. A radically twisted lipid regulates vascular death. Nat Med 2005, 11:1275-1276.
41. Long E.K., Murphy T.C., Leiphon L.J., Watt J., Morrow J.D., Milne G.L., et al. Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22:6; n-3) acid oxidation. J Neurochem 2008, 105:714-724.
42. Erl W., Weber C., Zernecke A., Neuzil J., Vosseler C.A., Kim H.J., Weber P.C. Cyclopentenone prostaglandins induce endothelial cell apoptosis independent of the peroxisome proliferator-activated receptor-gamma. Eur J Immunol 2004, 34:241-250.
43. Long E.K., Murphy T.C., Leiphon L.J., Watt J., Morrow J.D., Milne G.L., et al. Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22:6; n-3) acid oxidation. J Neurochem 2008, 105:714-724.
44. Gao L., Wang J., Sekhar K.R., Yin H., Yared N.F., Schneider S.N., et al. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J Biol Chem 2007, 282:2529-2537.
45. Acevedo L.M., Weis S.M., Cheresh D.A. Robo4 counteracts VEGF signaling. Nat Med 2008, 14:372-373.
46. Jones C.A., London N.R., Chen H., Park W., Sauaget D., Stockton R.A., et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med 2008, 14:448-453.
47. Gridley T. Vessel guidance. Nature 2007, 445:722-723.
48. Wilson B.D., Li M., Park K.W., Suli A., Sorensen L.K., Larrieu-Lahargue F., et al. Netrins promote developmental and therapeutic angiogenesis. Science 2006, 313:640-644.
49. Das U.N. Polyunsaturated fatty acids in pathological retinal angiogenesis. Curr Nutr Food Sci 2009, 5:94-111.
50. Gao L., Wang J., Sekhar K.R., Yin H., Yared N.F., Schneider S.N., et al. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J Biol Chem 2007, 282:2529-2537.
51. Acevedo L.M., Weis S.M., Cheresh D.A. Robo4 counteracts VEGF signaling. Nat Med 2008, 14:372-373.
52. Jones C.A., London N.R., Chen H., Park W., Sauaget D., Stockton R.A., et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med 2008, 14:448-453.
53. Gridley T. Vessel guidance. Nature 2007, 445:722-723.
54. Wilson B.D., Li M., Park K.W., Suli A., Sorensen L.K., Larrieu-Lahargue F., et al. Netrins promote developmental and therapeutic angiogenesis. Science 2006, 313:640-644.
55. Mitchell S., Thomas G., Harvey K., Cottell D., Reville K., Berlasconi G., et al. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 2002, 13:2497-2507.
56. Das U.N. Essential fatty acids and their metabolites could function as endogenous HMG- CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis 2008, 7:37.
57. Das U.N. Lipoxins, resolvins, protectins, maresins and nitrolipids: connecting lipids, inflammation, and cardiovascular disease risk. Curr Cardiovasc Risk Rep 2010, 4:24-31.
58. Das U.N. Essential fatty acid metabolism in patients with essential hypertension, diabetes mellitus and coronary heart disease. Prostaglandins Leukot Essent Fatty Acids 1995, 52:387-391.
59. Serhan C.N. Novel chemical mediators in the resolution of inflammation: resolvins and protectins. Anesthesiol Clin 2006, 24:341-364.
60. Kang J.X., Weylandt K.H. Modulation of inflammatory cytokines by omega-3 fatty acids. Subcell Biochem 2008, 49:133-143.
61. Chen H., Ray J., Scarpino V., Acland G.M., Aguirre G.D., Anderson R.E. Synthesis and release of docosahexaenoic acid by the RPE cells of prcd-affected dogs. Invest Ophthalmol Vis Sci 1999, 40:2418-2422.
62. Chen H., Anderson R.E. Metabolism in frog retinal pigment epithelium of docosahexaenoic and arachidonic acids derived from rod outer segment membranes. Exp Eye Res 1993, 57:369-377.
63. Chen H., Anderson R.E. Differential incorporation of docosahexaenoic and arachidonic acids in frog retinal pigment epithelium. J Lipid Res 1993, 34:1943-1955.
64. Wang N., Anderson R.E. Synthesis of docosahexaenoic acid by retina and retinal pigment epithelium. Biochemistry 1993, 32:1373-1379.
65. Zhang Y.W., Morita I., Yao X.S., Murota S. Pretreatment with eicosapentaenoic acid prevented hypoxia/reoxygenation-induced abnormality in endothelial gap junctional intercellular communication through inhibiting the tyrosine kinase activity. Prostaglandins Leukot Essent Fatty Acids 1999, 61:33-40.
66. Zhang Y.W., Yao X.S., Murota S., Morita I. Inhibitory effects of eicosapentaenoic acid (EPA) on the hypoxia/reoxygenation-induced tyrosine kinase activation in cultured human umbilical vein endothelial cells. Prostaglandins Leukot Essent Fatty Acids 2002, 67:253-261.
67. Yang S.P., Morita I., Murota S.I. Eicosapentaenoic acid attenuates vascular endothelial growth factor-induced proliferation via inhibiting Flk-1 receptor expression in bovine carotid artery endothelial cells. J Cell Physiol 1998, 176:342-349.
68. Morita I., Zhang Y.W., Murota S.I. Eicosapentaenoic acid protects endothelial cell function injured by hypoxia/reoxygenation. Ann N Y Acad Sci 2001, 947:394-397.
69. Leedom A.J., Sullivan A.B., Dong B., Lau D., Gronert K. Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury. Am J Pathol 2010, 176:74-84.
70. Connor K.M., SanGiovanni J.P., Lofqvist C., Aderman C.M., Chen J., Higuchi A., et al. Increased dietary intake of ω-3 polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007, 7:868-873.
71. Das U.N. Clinical laboratory tools to diagnose inflammation. Adv Clin Chem 2006, 41:189-229.
72. Fierro I.M., Kutok J.L., Serhan C.N. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther 2002, 300:385-392.
73. Cezar-de-Mello P.F., Nascimento-Silva V., Villela C.G., Fierro I.M. Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene 2006, 25:122-129.
74. Cezar-de-Mello P.F., Vieira A.M., Nascimento-Silva V., Villela C.G., Barja-Fidalgo C., Fierro I.M. ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. Br J Pharmacol 2008, 153:956-965.
75. Baker N., O'Meara S.J., Scannell M., Maderna P., Godson C. Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells. J Immunol 2009, 182:3819-3826.
76. Jin Y., Arita M., Zhang Q., Saban D.R., Chauhan S.K., Chiang N., et al. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci 2009, 50:4743-4752.
77. Chen Y., Hao H., He S., Cai L., Li Y., Hu S., et al. Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis. Mol Cancer Ther 2010, 9:2164-2174.
78. Das U.N. Pathological retinal angiogenesis and polyunsaturated fatty acids. Agric Food Industry hi-tech 2008, 19:44-49.
79. Lobov I.B., Cheung E., Wudali R., Cao J., Halaz G., Wei Y., et al. The Dll4/Notch pathway controls postangiogenic blood vessel remodeling and regression by modulating vasoconstriction and blood flow. Blood 2011, 117:6728-6737.
80. Delbosc S., Glorian M., Le Port A.S., Béréziat G., Andréani M., Limon I. The benefit of docosahexaenoic acid on the migration of vascular smooth muscle cells is partially dependent on Notch regulation of MMP-2/-9. Am J Pathol 2008, 172:1430-1440.
81. Lee S.H., Kim M.H., Han H.J. Arachidonic acid potentiates hypoxia-induced VEGF expression in mouse embryonic stem cells: involvement of Notch, Wnt, and HIF-1alpha. Am J Physiol Cell Physiol 2009, 297:C207-C216.
82. Das U.N. Influence of polyunsaturated fatty acids and their metabolites on stem cell biology. Nutrition 2011, 27:21-25.
83. Das U.N. Radiation resistance, invasiveness and metastasis are inflammatory events that could be suppressed by lipoxin A(4). Prostaglandins Leukot Essent Fatty Acids 2012, 86:3-11.
84. Das U.N. Essential fatty acids and their metabolites as modulators of stem cell biology with reference to inflammation, cancer and metastasis. Cancer Metastasis Rev 2011, 30:311-324.
85. Das U.N. Is lipoxins A4 a better alternative to anti-VEGF and anti-TNF-alpha antibody to prevent and treat age-related macular degeneration, diabetic macular edema and retinopathy?. Med Sci Monit 2011, 18:LE1-LE2.